'The F.D.A. is expected to soon authorize Pfizer-BioNTech's booster for 5- to 11-year-olds.' -NY Times

Why Pfizer Partner BioNTech Shares Are Rising Today

The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies

Pfizer/BioNTech's Updated Omicron-Based COVID-19 Shots Show Improved Response Against Variant

Pfizer and BioNTech Announced Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron

The Daily Biotech Pulse: European Backing For Novavax's COVID-19 Shot In Adolescents, Sanofi-GSK's Updated Vaccine Effective Against Omicron, FDA's Clinical Hold On Sarepta's Duchenne Trial